Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/209129
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Inciarte Mundo, José | - |
dc.contributor.author | Frade Sosa, Beatriz | - |
dc.contributor.author | Sanmartí Sala, Raimon | - |
dc.date.accessioned | 2024-03-25T10:55:58Z | - |
dc.date.available | 2024-03-25T10:55:58Z | - |
dc.date.issued | 2022-11-03 | - |
dc.identifier.issn | 1664-3224 | - |
dc.identifier.uri | http://hdl.handle.net/2445/209129 | - |
dc.description.abstract | S100A9/S100A8 (calprotectin), a member of the S100 protein family, has been shown to play a pivotal role in innate immunity activation. Calprotectin plays a critical role in the pathogenesis of rheumatoid arthritis (RA), as it triggers chemotaxis, phagocyte migration and modulation of neutrophils and macrophages. Higher calprotectin levels have been found in synovial fluid, plasma, and serum from RA patients. Recent studies have demonstrated better correlations between serum or plasma calprotectin and composite inflammatory disease activity indexes than c-reactive protein (CRP) or the erythrocyte sedimentation rate (ESR). Calprotectin serum levels decreased after treatment, independently of the DMARD type or strategy. Calprotectin has shown the strongest correlations with other sensitive techniques to detect inflammation, such as ultrasound. Calprotectin independently predicts radiographic progression. However, its value as a biomarker of treatment response and flare after tapering is unclear. This update reviews the current understanding of calprotectin in RA and discusses possible applications as a biomarker in clinical practice. | - |
dc.format.extent | 13 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Frontiers Media SA | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3389/fimmu.2022.1001025 | - |
dc.relation.ispartof | Frontiers In Immunology, 2022, vol. 13, p. 1001025 | - |
dc.relation.uri | https://doi.org/10.3389/fimmu.2022.1001025 | - |
dc.rights | cc by (c) Inciarte Mundo, José et al., 2022 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) | - |
dc.subject.classification | Artritis reumatoide | - |
dc.subject.classification | Marcadors bioquímics | - |
dc.subject.other | Rheumatoid arthritis | - |
dc.subject.other | Biochemical markers | - |
dc.title | From bench to bedside: Calprotectin (S100A8/S100A9) as a biomarker in rheumatoid arthritis | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2023-06-28T08:37:09Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.idimarina | 9332661 | - |
dc.identifier.pmid | 36405711 | - |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
From bench to bedside Calprotectin (S100A8 S100A9) as a biomarker_FrontiersInImmunology.pdf | 2.63 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License